This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Ejzykowicz F, Hay JW.Cost-effectiveness analysis of lapatinib plus capecitabine versus capecitabine alone in the second line treatment for breast cancer treatment. Value in Health 11: A60-A61, No. 3, May-Jun 2008
Lal LS, Arbuckle R.A cost-effectiveness analysis of lapatinib at a tertiary cancer center. Value in Health 11: A59, No. 3, May-Jun 2008
Rights and permissions
About this article
Cite this article
Is it worth using lapatinib for advanced breast cancer?. Pharmacoecon. Outcomes News 555, 4 (2008). https://doi.org/10.2165/00151234-200805550-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805550-00004